UnitedHealth (UNH) shares are resilient despite reports of investigation by the U.S. Justice Department into pharmacy benefit manager Optum Rx and physician reimbursement practices. Stock has surged 30% since Warren Buffett disclosed a stake. The probe could lead to fines or operational changes, impacting future earnings and stock recovery.

Investor sentiment towards UnitedHealth remains fragile amid regulatory scrutiny and margin compression. Despite short-term resilience, the stock faces legal and reputational risks. High-profile investors like Warren Buffett, David Tepper, and Michael Burry have shown interest, attracted by the stock’s value and dividend yield. UNH is cooperating with the DOJ and maintains confidence in its business practices.

Wall Street analysts advise caution despite the stock’s attractive valuation. The consensus remains at “Moderate Buy” with a mean target of around $309, indicating limited upside potential. Investors should carefully consider the risks and uncertainties associated with UnitedHealth stock.

Read more at Yahoo Finance: The UnitedHealth Probe Is Bigger Than Investors Previously Thought. What Does That Mean for UNH Stock?